Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02650921 · ClinicalTrials.gov registry record · NA
Effectiveness and Safety of Restylane Lyft With Lidocaine in the Dorsal Hand
A NA study, sponsored by Galderma R&D.
- Completed
- Registry status
- NA
- Development phase
- 92
- Enrollment target
NCT02650921: Completed NA study, sponsored by Galderma R&D.
NCT02650921 is a NA study that has completed, run by Galderma R&D. The registered enrollment target is 92 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02650921, a NA study, has completed, sponsored by Galderma R&D.
- COMPLETED
- Registry status
- NA
- Development phase
- 92 participants
- Enrollment target
Study Summary
This is a randomized, evaluator-blind, split hand, multi-center study of the effectiveness and safety or Restylane Lyft with Lidocaine compared to no treatment for injection in the dorsal hand to correct volume deficits.
Primary Outcome
A responder is defined as a hand with at least one improvement from baseline.
Interventions
- DEVICE Restylane Lyft with Lidocaine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 92 participants |
| Start Date | 2015-12 |
| Est. Completion | 2016-12 |
| Phase | NA |
What the finished NCT02650921 record still lists
NCT02650921 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 92 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower).
The record links to 0 conditions, and to 1 intervention - of which Restylane Lyft with Lidocaine is the first listed.
NCT02650921 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02650921 about?
NCT02650921 is a clinical study titled "Effectiveness and Safety of Restylane Lyft With Lidocaine in the Dorsal Hand". This is a randomized, evaluator-blind, split hand, multi-center study of the effectiveness and safety or Restylane Lyft with Lidocaine compared to no treatment for injection in the dorsal hand to correct volume deficits.
What is the current status of trial NCT02650921?
This trial is currently completed. It is a NA study. The enrollment target is 92 participants. The study started on 2015-12. Estimated completion is 2016-12.
What interventions are being tested in trial NCT02650921?
The interventions under investigation include: Restylane Lyft with Lidocaine (DEVICE).
Who is sponsoring clinical trial NCT02650921?
This trial is sponsored by Galderma R&D, which has 158 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02650921's enrollment target sits among peer trials
92 937th of 2000 higher than 1,062 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03184545 · 92 participants · Phase 3
Comparing the Outcome of Electrical Stimulation and Physical Therapy in Patellofemoral Pain Syndrome
- NCT04172532 · 92 participants · Phase 1
Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer
- NCT04508088 · 92 participants
Skeletal Health and Bone Marrow Composition in Newly Diagnosed Adolescents With Crohn Disease
- NCT04840602 · 92 participants · Phase 2
Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia